Epidemiology of Nontuberculous Mycobacteria Infection in Children and Young People With Cystic Fibrosis: Analysis of UK Cystic Fibrosis Registry.
NTM
children
cystic fibrosis
epidemiology
nontuberculous mycobacteria
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
received:
09
05
2018
accepted:
29
06
2018
pubmed:
10
7
2018
medline:
9
4
2020
entrez:
9
7
2018
Statut:
ppublish
Résumé
Infection with nontuberculous mycobacteria (NTM) is of growing clinical concern in people with cystic fibrosis (CF). The epidemiology of infection in children and young people remains poorly understood. Our goal was to investigate the epidemiology of NTM infection in the pediatric age group using data from the UK CF Registry. Data from 2010-2015 for individuals aged <16 years (23200 observations from 5333 unique individuals) were obtained. Univariate analysis of unique individuals comparing all key clinical factors and health outcomes to NTM status was performed. The significant factors that were identified were used to generate a multivariate logistic regression model that, following step-wise removal, generated a final parsimonious model. The prevalence of individuals with a NTM-positive respiratory culture increased every year from 2010 (45 [1.3%]) to 2015 (156 [3.8%]). Allergic bronchopulmonary aspergillosis (odds ratio [OR], 2.66; P = 5.0 × 10-8), age (OR, 1.08; P = 3.4 × 10-10), and intermittent Pseudomonas aeruginosa infection (OR, 1.51; P = .004) were significantly associated with NTM infection. NTM infection is of increasing prevalence in the UK pediatric CF population. This study highlights the urgent need for work to establish effective treatment and prevention strategies for NTM infection in young people with CF.
Sections du résumé
BACKGROUND
Infection with nontuberculous mycobacteria (NTM) is of growing clinical concern in people with cystic fibrosis (CF). The epidemiology of infection in children and young people remains poorly understood. Our goal was to investigate the epidemiology of NTM infection in the pediatric age group using data from the UK CF Registry.
METHODS
Data from 2010-2015 for individuals aged <16 years (23200 observations from 5333 unique individuals) were obtained. Univariate analysis of unique individuals comparing all key clinical factors and health outcomes to NTM status was performed. The significant factors that were identified were used to generate a multivariate logistic regression model that, following step-wise removal, generated a final parsimonious model.
RESULTS
The prevalence of individuals with a NTM-positive respiratory culture increased every year from 2010 (45 [1.3%]) to 2015 (156 [3.8%]). Allergic bronchopulmonary aspergillosis (odds ratio [OR], 2.66; P = 5.0 × 10-8), age (OR, 1.08; P = 3.4 × 10-10), and intermittent Pseudomonas aeruginosa infection (OR, 1.51; P = .004) were significantly associated with NTM infection.
CONCLUSIONS
NTM infection is of increasing prevalence in the UK pediatric CF population. This study highlights the urgent need for work to establish effective treatment and prevention strategies for NTM infection in young people with CF.
Identifiants
pubmed: 29982302
pii: 5049416
doi: 10.1093/cid/ciy531
pmc: PMC6376093
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
731-737Subventions
Organisme : Medical Research Council
ID : MR/M008797/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Cyst Fibros. 2016 Sep;15(5):619-23
pubmed: 27050794
Curr Opin Pulm Med. 2013 Nov;19(6):662-9
pubmed: 24048085
Eur Respir J. 2017 Sep 20;50(3):
pubmed: 28931659
J Clin Microbiol. 2016 Aug;54(8):2047-50
pubmed: 27225412
BMC Pulm Med. 2018 May 22;18(1):86
pubmed: 29788939
Science. 2016 Nov 11;354(6313):751-757
pubmed: 27846606
J Cyst Fibros. 2010 Mar;9(2):117-23
pubmed: 20071249
Am J Respir Crit Care Med. 2010 Oct 1;182(7):977-82
pubmed: 20508209
J Cyst Fibros. 2015 Jan;14(1):53-62
pubmed: 24917112
J Cyst Fibros. 2015 Jan;14(1):46-52
pubmed: 25178871
J Clin Microbiol. 2007 May;45(5):1497-504
pubmed: 17376883
Ann Am Thorac Soc. 2014 Jan;11(1):36-44
pubmed: 24251858
J Clin Microbiol. 2017 May;55(5):1469-1477
pubmed: 28228494
J Clin Microbiol. 2009 Dec;47(12):4124-8
pubmed: 19846643
Lancet. 2013 May 4;381(9877):1551-60
pubmed: 23541540
Am J Respir Crit Care Med. 2012 Oct 1;186(7):684-91
pubmed: 22859521
Thorax. 2016 Jan;71(1):88-90
pubmed: 26678435
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
J Cyst Fibros. 2016 May;15(3):380-5
pubmed: 26482717
Lancet. 2016 Nov 19;388(10059):2519-2531
pubmed: 27140670
Int J Epidemiol. 2018 Feb 1;47(1):9-10e
pubmed: 29040601
J Cyst Fibros. 2016 Mar;15(2):186-91
pubmed: 26002312
Am J Respir Crit Care Med. 2012 Jan 15;185(2):231-2
pubmed: 22246710
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64
pubmed: 29054853